GPC1 and posterior cortical atrophy: In conclusion, our data describe the potential utility of [89Zr]Zr-DFO-Miltuximab® as an imaging agent for GPC-1 expressing PCa and [177Lu]Lu-DOTA-Miltuximab® as a targeted radiotherapy.